Genomes and Genes
S D Mikolajczyk
Affiliation: Beckman Coulter
- Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign diseaseStephen D Mikolajczyk
Beckman Coulter, Inc, San Diego, CA, USA
Rinsho Byori 52:223-30. 2004..The BPH-associated BPSA and cancer-associated proPSA forms are complementary and provide improved detection of prostate cancer from benign disease...
- Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancerYoshio Naya
Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
Urol Oncol 23:16-21. 2005..Disease-associated isoforms of the prostate-specific antigen (PSA) have recently been identified. We evaluated the efficacy of using precursor isoforms of PSA (pPSA) and their ratios for the detection of prostate cancer...
- Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2S D Mikolajczyk
Hybritech Incorporated, San Diego, California 92196 9006, USA
Eur J Biochem 246:440-6. 1997..These results indicate that Ala217 is a key residue affecting the catalytic properties of hK2...
- Are multiple markers the future of prostate cancer diagnostics?Stephen D Mikolajczyk
Beckman Coulter, Inc, San Diego, CA 92121, USA
Clin Biochem 37:519-28. 2004....
- A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancerS D Mikolajczyk
Hybritech, Inc, San Diego, California 92121, USA
Cancer Res 61:6958-63. 2001..Thus, [-2]pPSA, once formed, is a stable but inactive isoform of PSA. Truncated [-2]pPSA may represent an important new diagnostic marker for the early detection of PCa...
- Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancerStephen D Mikolajczyk
Beckman Coulter, Inc, San Diego, CA, USA
Clin Chem 50:1017-25. 2004..Immunoassays were developed to measure specific proPSA forms containing propeptides of 2, 4, and 7 amino acids [(-2)proPSA, (-4)proPSA, and (-7)proPSA, respectively]...
- Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasiaS D Mikolajczyk
Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, San Diego, California 92196 9006, USA
Prostate 45:271-6. 2000..BPSA was purified and found to contain a characteristic clip between Lys182 and Ser183. We now describe the identification of BPSA in seminal plasma...
- A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissueS D Mikolajczyk
Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, San Diego, CA 92121, USA
Cancer Res 60:756-9. 2000..These results demonstrate that pPSA is more highly correlated with prostate cancer than with BPH. The pPSA in serum may represent a more cancer-specific form of PSA that could help distinguish prostate cancer from BPH...
- Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissueS D Mikolajczyk
Hybritech Inc, San Diego, California 92121, USA
Cancer Res 59:3927-30. 1999..The physiological role of PI-6 in the prostate and its relationship to hK2 and prostate cancer are under investigation...
- Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1S D Mikolajczyk
Hybritech Incorporated, a subsidiary of Beckman Coulter Inc, San Diego, CA 92196 9006, USA
Int J Cancer 81:438-42. 1999..Our current results suggest that the increased hK2 expression in prostate cancer tissues could influence cancer biology not only by activation of uPA but also by inactivation of its primary inhibitor, PAI-1...
- The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasiaM S Saedi
Hybritech Incorporated, Beckman Coulter, Inc, San Diego, CA 92126, USA
Clin Chem 44:2115-9. 1998..In addition, prohK2 in human sera is associated with prostate disease and thus may be a useful marker for prostatic cancer and BPH...
- Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cellsM S Saedi
Hybritech Inc, San Diego, CA, USA
Int J Cancer 94:558-63. 2001..The differential staining pattern of PI6 in tissues suggests a complex regulation of PI-6 expression that may play a role in other aspects of neoplastic progression...
- Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitorsS D Mikolajczyk
Hybritech Incorporated, San Diego, CA 92196 9006, USA
Prostate 34:44-50. 1998..It is a serine protease expressed in human prostate epithelial cells which has 78% sequence identity with prostate-specific antigen (PSA). PSA is a widely used biochemical marker for prostate cancer...
- Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodiesT J Wang
Hybritech Incorporated, San Diego, USA Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, USA
Eur J Biochem 267:4040-5. 2000..Measurement of BPSA levels in the serum may help discriminate benign prostatic hyperplasia from early prostate cancer...
- Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostateH G Rittenhouse
Research and Development Department, Hybritech Incorporated, Beckman Coulter, Inc, San Diego, California, USA
Crit Rev Clin Lab Sci 35:275-368. 1998..The production of hK2 protein in active protease form and specific monoclonal antibodies to the hK2 antigen will allow extensive future studies delineating the physiological and clinical utility of this new prostate antigen...
- Development of a dual monoclonal antibody immunoassay for total human kallikrein 2J A Finlay
Research Department, Hybritech Inc, a subsidiary of Beckman Coulter, Inc, San Diego, CA 92121, USA
Clin Chem 47:1218-24. 2001....
- Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancerAnil V Parwani
Division of Pathology Informatics and Genito Urinary Pathology, Univeristy of Pittsburgh Medical Center Shadyside Hospital, Department of Pathology, Pittsburgh, PA 15232, USA
Am J Surg Pathol 30:1231-6. 2006..A panel of markers, including proPSA, should be performed when metastatic prostate carcinoma is in the differential diagnosis...
- Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancerEduardo I Canto
Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
Urology 63:905-10; discussion 910-1. 2004....
- Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigenWilliam J Catalona
Washington University, St Louis, Missouri, USA
J Urol 171:2239-44. 2004..Pro forms of prostate specific antigen (PSA) have been reported to be more cancer specific markers of prostate cancer than total PSA and they also may preferentially detect the more aggressive forms of the disease...
- Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancerYoshio Naya
Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Urology 63:492-8. 2004..We evaluated the efficacy of precursor isoforms of PSA (pPSA) and an internally cleaved form of PSA referred to as the benign prostatic hyperplasia-associated PSA (BPSA) for the detection of prostate cancer...
- Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/mlWilliam J Catalona
Washington University, St Louis, Missouri, USA
J Urol 170:2181-5. 2003..Serum pPSA was measured in the clinically relevant early detection PSA range of 2 to 10 ng/ml...
- Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/mlMasood A Khan
James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
J Urol 170:723-6. 2003..There is increasing evidence that proPSA is associated preferentially with prostate cancer. The objective of this study was to determine whether proPSA can influence the detection of early prostate cancer...
- Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancerRobert W Veltri
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Urology 68:898-904. 2006..To differentiate the benign and/or malignant epithelial cells in prostate cancer (PCa) glands of native Japanese (NJ) and Japanese-American (JA) men using biomarkers...
- Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigenTheresa Y Chan
Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
Urology 62:177-81. 2003..Pro-PSA have previously been shown to be more concentrated in prostate cancer tissue extracts than in benign tissue...
- Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysisLori J Sokoll
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Urology 61:274-6. 2003..5 to 4.0 ng/mL total PSA range. pPSA, the precursor form of PSA that contains a 7 amino acid leader peptide, and truncated forms such as [-2]pPSA and [-4]pPSA can be measured in serum by research immunoassay...
- Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate diseaseHarry J Linton
Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, 7330 Carroll Road, San Diego, CA 92121, USA
Clin Chem 49:253-9. 2003..We developed an immunoassay to determine the concentration of BPSA in the serum of men with BPH...
- Free prostate-specific antigen in serum is becoming more complexStephen D Mikolajczyk
Hybritech Incorporated, San Diego, California 92121, USA
Urology 59:797-802. 2002
- Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progressionIacovos P Michael
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
J Biol Chem 281:12743-50. 2006..Our results uncover a kallikrein proteolytic cascade pathway in the prostate that participates in seminal clot liquefaction and probably in prostate cancer progression...
- Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndromeRobert B Nadler
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Urology 67:337-42. 2006....
- Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%Masood A Khan
Department of Urology, James Buchanan Brady Urological Institute and the Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, USA
Urology 64:1160-4. 2004..A low percent free PSA value indicates a greater risk of cancer, but only 30% to 50% of men with percent free PSA levels of less than 15% actually have cancer at biopsy...
- Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancerStephen D Mikolajczyk
Beckman Coulter, Inc, San Diego, CA 92121 2302, USA
Keio J Med 52:86-91. 2003..001). ProPSA was superior to %FPSA and complexed PSA in the 4-10 ng/ml PSA range (AUC = 0.689, 0.637 and 0.538, respectively). ProPSA represents a more cancer-specific form of PSA that better discriminates prostate cancer from BPH...
- Prostate specific antigen assay standardization bias could affect clinical decision makingStacy Loeb
Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Urol 180:1959-62; discussion 1962-3. 2008..Most commercial prostate specific antigen assays are standardized to the WHO 90:10 standard or aligned with the original Hybritech assay with potentially disparate results...